Livestock

More than 45 per cent of Boehringer Ingelheim Animal Health Business Unit’s global revenue comes from our livestock business (poultry, ruminant, swine and Veterinary Public Health), driven by innovative parasiticides, vaccines and therapeutics, as well as our history of partnership with livestock producers, livestock veterinarians, government officials and NGOs.

We take responsibility seriously by bringing innovative health solutions to our customers. We focus our solutions on innovation that prevent disease in livestock. In doing so, we help livestock producers produce more high quality food using less natural resources.

We also strive to address some of the most pressing challenges facing our livestock customers, such as the need to cost-effectively produce more protein to feed the world's growing population. By 2050, the global population will reach 9.7 billion people, with a significant increase in the middle class, and substantial growth in emerging markets like Africa and Asia. As a result, the demand for animal protein is expected to increase by 70 per cent. 

In response to a growing public health concern over antibiotic resistance and the need for food safety, we strive to develop solutions that prevent or reduce the need for antibiotics while at the same time improving the quality and safety of our food.

Last but not least, we help our customers tackle these challenges with preventive care solutions. Furthermore, we are increasing our focus on non-traditional animal health offerings, such as point-of-care diagnostic technologies, live therapeutics, and digital solutions.